Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations: a systematic review and meta-analysis

References

• GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–1544.
   PubMed Web of Science ®Google Scholar
• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391:1706–1717.
   PubMed Web of Science ®Google Scholar
• Ni W, Shao X, Cai X, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One. 2015;10:e0121257.
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Pekow PS, Lahti M, et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010;303:2035–2042.
   PubMed Web of Science ®Google Scholar
• Chan HP, Lim TK. Procalcitonin and antibiotics in moderate-severe acute exacerbation of chronic obstructive pulmonary disease: to use or not to use. Curr Opin Pulm Med. 2019;25:150–157.
   PubMed Web of Science ®Google Scholar
• Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. Respirology. 2016;21:1152–1165.
   PubMed Web of Science ®Google Scholar
• Sager R, Kutz A, Mueller B, et al. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med. 2017;15:15.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18:95–107.
   PubMed Web of Science ®Google Scholar
• de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16:819–827.
   PubMed Web of Science ®Google Scholar
• Desai H, Eschberger K, Wrona C, et al. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11:303–309.
   PubMedGoogle Scholar
• Su YC, Jalalvand F, Thegerström J, et al. The interplay between immune response and bacterial infection in COPD: focus upon non-typeable haemophilus influenzae. Front Immunol. 2018;9:2530.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Deeks JJ, Altman DG. Special topics in statistics. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions Version 5.1.0. Chapter 7. The Cochrane Collaboration; 2011. p. 19–21. Available from: https://training.cochrane.org/handbook.
   Google Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: Introduction GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–394.
   PubMed Web of Science ®Google Scholar
• Chang C, Yao WZ, Chen YH, et al. The changes and clinical implications of serum procalcitonin in acute exacerbations of chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi. 2006;29:444–447.
   PubMedGoogle Scholar
• Daubin C, Parienti JJ, Vabret A, et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study. BMC Infect Dis. 2008;8:145.
   PubMed Web of Science ®Google Scholar
• Nseir S, Cavestri B, Di Pompeo C, et al. Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration. 2008;76:253–260.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Becker KL, Swinburne AJ, et al. Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note. Int J Chron Obstruct Pulmon Dis. 2012;7:127–135.
   PubMed Web of Science ®Google Scholar
• Tanrıverdi H, Örnek T, Erboy F, et al. Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD. Wien Klin Wochenschr. 2015;127:756–763.
   PubMed Web of Science ®Google Scholar
• Ergan B, Şahin AA, Topeli A. Serum procalcitonin as a biomarker for the prediction of bacterial exacerbation and mortality in severe COPD exacerbations requiring mechanical ventilation. Respiration. 2016;91:316–324.
   PubMed Web of Science ®Google Scholar
• Li Y, Xie L, Xin S, et al. Values of procalcitonin and C-reactive proteins in the diagnosis and treatment of chronic obstructive pulmonary disease having concomitant bacterial infection. Pak J Med Sci. 2017;33:566–569.
   PubMed Web of Science ®Google Scholar
• Xiong G, Qiao B, Wu Z, et al. Diagnostic values of C-reactive protein, procalcitonin and serum amyloid A in predicting bacterial infection in patients with acute exacerbations of chronic obstructive pulmonary disease. Int J Clin Exp Med. 2018;11:7118–7124.
   Web of Science ®Google Scholar
• Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–607.
   PubMed Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9–19.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302:1059–1066.
   PubMed Web of Science ®Google Scholar
• Nangia V, Gandhi K. Use of procalcitonin to guide the antibiotic therapy in patients with an acute exacerbation of COPD in a resource-limited setting: a case-control study. Clin Microbiol Infect. 2012;18:O404.
   Google Scholar
• Liu SS, Zhang YB. The value of serum procalcitonin level in guiding the use of antibiotic in patients with acute exacerbation of chronic obstructive pulmonary disease. Chin J Antibiot. 2015;40:459–463.
   Google Scholar
• Verduri A, Luppi F, D’Amico R, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PloS One. 2015;10:e0118241.
   PubMed Web of Science ®Google Scholar
• Corti C, Fally M, Fabricius-Bjerre A, et al. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1381–1389.
   PubMed Web of Science ®Google Scholar
• Daubin C, Valette X, Thiollière F, et al. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. Intensive Care Med. 2018;44:428–437.
   PubMed Web of Science ®Google Scholar
• Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379:236–249.
   PubMed Web of Science ®Google Scholar
• Picart J, Moiton MP, Gaüzère BA, et al. Introduction of a PCT-based algorithm to guide antibiotic prescription in COPD exacerbation. Med Mal Infect. 2016;46:429–435.
   PubMed Web of Science ®Google Scholar
• Bremmer DN, DiSilvio BE, Hammer C, et al. Impact of procalcitonin guidance on management of adults hospitalized with chronic obstructive pulmonary disease exacerbations. J Gen Intern Med. 2018;33:692–697.
   PubMed Web of Science ®Google Scholar
• Sabrine N, Nejla T, Habiba S. Procalcitonin guided antibiotic therapy during severe acute exacerbation of chronic obstructive pulmonary disease requiring mechanical ventilation: a before after study. Ann Intens Care. 2018;8(Suppl 1):42.
   Google Scholar
• Townsend J, Adams V, Galiatsatos P, et al. Procalcitonin-guided antibiotic therapy reduces antibiotic use for lower respiratory tract infections in a united states medical center: results of a clinical trial. Open Forum Infect Dis. 2018;5:ofy327.
   PubMed Web of Science ®Google Scholar
• Wang JX, Zhang SM, Li XH, et al. Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. Int J Infect Dis. 2016;48:40–45.
   PubMed Web of Science ®Google Scholar
• Bremmer DN, Moffa MA, Ma K, et al. Acute exacerbations of chronic obstructive pulmonary disease with a low procalcitonin concentration: impact of antibiotic therapy. Clin Infect Dis. 2019;68:725–730.
   PubMed Web of Science ®Google Scholar
• Jacobs DM, Pandit U, Sethi S. Acute exacerbations in chronic obstructive pulmonary disease: should we use antibiotics and if so, which ones? Curr Opin Infect Dis. 2019;32:143–151.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019. Available from: www.goldcopd.org [Last accessed on February 01, 2019].
   Google Scholar
• Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36:941–952.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011;9:107.
   PubMed Web of Science ®Google Scholar
• Pfister R, Kochanek M, Leygeber T, et al. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis. Crit Care. 2014;18:R44.
   PubMed Web of Science ®Google Scholar
• Wang J, Cao B. Procalcitonin and other markers to guide antibiotic use in chronic obstructive pulmonary disease exacerbations in the era of antimicrobial resistance. Curr Opin Pulm Med. 2019;25:158–164.
   PubMed Web of Science ®Google Scholar
• Soler N, Esperatti M, Ewig S, et al. Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J. 2012;40:1344–1353.
   PubMed Web of Science ®Google Scholar
• Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, et al. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev. 2017;26:pii:160073.
   Web of Science ®Google Scholar
• Lin C, Pang Q. Meta-analysis and systematic review of procalcitonin-guided treatment in acute exacerbation of chronic obstructive pulmonary disease. Clin Respir J. 2018;12:10–15.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters. Am J Respir Crit Care Med. 2011;184:662–671.
   PubMed Web of Science ®Google Scholar
• Vollenweider DJ, Frei A, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;10:CD010257.
   PubMedGoogle Scholar